OncoGenex Pharmaceuticals - Update on OGX-427
Jun 20th 2012 - Edison Investment Research today published a report on OncoGenex Pharmaceuticals entitled "Update On OGX-427". In summary, the report says:
Further data on OncoGenex’s OGX-427 continue to indicate that the product has significant potential in castration resistant prostate cancer (CRPC), even with the advances that are occurring. J&J’s abiraterone (Zytiga) and Medivation’s MDV3100 will probably be used routinely before chemotherapy for treating CRPC. OGX-427’s mechanism of action suggests it could be a complementary therapy to these drugs, a hypothesis that will soon be tested in a Phase II study with abiraterone. However, increased costs lead us to lower our valuation by $10m to $397m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
